L. Iglesias

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

Miguel Martín, Aňa Lluch, Miguel Ángel Seguí et al. · Annals of Oncology · 2006 · 204 citations · Full text

Medicine, Oncology, Pharmacology +17

Sorafenib in metastatic thyroid cancer

Jaume Capdevila, L. Iglesias, Irene Halperín et al. · Endocrine Related Cancer · 2012 · 111 citations · Full text

Medicine, Oncology, Pharmacology +14

SEOM clinical guidelines for the treatment of head and neck cancer (2020)

L. Iglesias, J. Lambea, Javier Martínez‐Trufero et al. · Clinical & Translational Oncology · 2021 · 103 citations · Full text

Medicine, Oncology, Surgery +17

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

Jan B. Vermorken, Frédéric Peyrade, John C. Krauss et al. · Annals of Oncology · 2014 · 94 citations · Full text

Medicine, Oncology, Pharmacology +17

Extended-schedule dose-dense temozolomide in refractory gliomas

Alfonso Berrocal, Pedro Pérez Segura, Carmen Balañá et al. · Journal of Neuro-Oncology · 2009 · 61 citations · Full text

Medicine, Oncology, Pharmacotherapy +17